Calidi Biotherapeutics Stock (AMEX: CLDI)

Dernières nouvelles pour Calidi Biotherapeutics (AMEX:CLDI) Stock

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Citigroup analyst Simon Hales maintains Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) with a Buy and raises the price target from $188 to $200.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Philip Morris Intl, Raises Price Target to $200

Citigroup analyst Christopher Allen maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and raises the price target from $137 to $160.

Citigroup Maintains Neutral on Blackstone, Raises Price Target to $160

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) has outperformed the market over the past 5 years by 1.21% on an annualized basis producing an average annual return of 15.64%. Currently, MetLife has a market capitalization of $52.70 billion. 
Buying $100 In MET: If an investor had bought $100 of MET stock 5 years ago, it would be worth $209.49 today based on a price of $78.37 for MET at the time of writing.
<h3>MetLife's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752183028_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In MetLife 5 Years Ago Would Be Worth This Much Today

Citigroup analyst James Hardiman maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Neutral and raises the price target from $48 to $50.

PRKS

Citigroup Maintains Neutral on United Parks & Resorts, Raises Price Target to $50

Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) shares traded lower Thursday, even as analysts raise their price targets ahead of the streaming giant&#8217;s second-quarter earnings report next week. Investors are looking to see if the company can build on its <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">strong first-quarter</a> performance and justify the recent stock rally.
What To Know: KeyBanc Capital Markets <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">boosted</a> its price target on Netflix to $1,390 from $1,070, citing confidence in long-term growth driven by live events, price increases, and an expanding advertising business. The firm anticipates revenue will continue to grow by double-digit percentages over the medium term. 
Netflix is scheduled to report its second-quarter earnings on Thursday, July 17. Analysts expect an EPS of $7.06 on $11.04 billion in revenue.
KeyBanc is even more bullish, forecasting second-quarter revenue of $11.2 billion and EPS of $7.20, slightly above consensus, attributing the potential upside to favorable foreign exchange rates. For the third quarter, KeyBanc expects revenue guidance to align with the Street&#8217;s $11.3 billion estimate.
Read Also: <a href="https://www.benzinga.com/news/sports/25/07/46330000/brad-pitt-effect-apple-wants-formula-1-tv-rights-after-box-office-success">Brad Pitt Effect: Apple Wants Formula 1 TV Rights After Box Office Success</a>
What Else: KeyBanc also highlights that Netflix&#8217;s focus on one-time live events, such as the upcoming Taylor vs. Serrano fight, is a strategic move to add value without committing to more expensive long-term sports rights. 
The firm also suggests that long-term investors remain optimistic due to the belief that Netflix is still under-monetized compared to traditional media, and that its technological expertise will enable it to leverage innovations in AdTech and AI more quickly than legacy competitors.
This technological edge, combined with a consistent track record of producing surprise content hits, is expected to support future monetization and engagement.
Looking ahead, analysts will likely be closely watching the performance of new live events and the impact of a weaker U.S. dollar on international revenue. 
While the <a href="https://www.benzinga.com/news/entertainment/25/06/46180148/netflixs-squid-game-ends-or-does-it">final season</a> of &#8220;Squid Game&#8221; was recently released, viewership is expected to be weighted toward the second half of the year, alongside the highly anticipated new seasons of &#8220;Wednesday&#8221; and &#8220;Stranger Things.&#8221;
Analyst Ratings: Recent <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">analyst ratings</a> have been mixed ahead of the earnings report. On July 10, Barclays also increased its price target, though more modestly, to $1100 from $1000, while maintaining an Equal-Weight rating. In a more cautious move, Seaport Global downgraded Netflix on July 7, changing its rating from Buy to Neutral.
Other analysts have also weighed in recently. On July 2, Canaccord Genuity maintained its Buy rating and increased its price target from $1380 to $1525. On the same day, Goldman Sachs also raised its price target, but only to $1140 from $1000, while reiterating a Neutral rating. 
Looking back to late June, Pivotal Research showcased strong optimism by maintaining its Buy rating and lifting its target to $1600 from $1350 on June 20.
Price Action: According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NFLX shares closed Thursday&#8217;s session lower by 2.93% to $1,250.59. The stock has a 52-week high of $1,341.15 and a 52-week low of $588.43.
Read Also: <a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/07/46347606/roku-called-self-help-turnaround-citing-profit-focus-and-new-ad-partners">Roku Called &#8216;Self-Help&#8217; Turnaround, Citing Profit Focus And New Ad Partners</a>
<h2 class="wp-block-heading">How To Buy NFLX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Netflix&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
NFLX Price Action: Netflix shares were down 2.90% at $1250.90 on Thursday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Image: Shutterstock

NFLX

Netflix Stock Dips Ahead Of Q2 Earnings Despite Analyst Optimism

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $50.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $50

Citigroup analyst Scott Gruber maintains TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Buy and raises the price target from $35 to $41.

Citigroup Maintains Buy on TechnipFMC, Raises Price Target to $41

Citigroup analyst Scott Gruber downgrades Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) from Buy to Neutral and lowers the price target from $35 to $32.

Downgrades

Citigroup Downgrades Noble Corp to Neutral, Lowers Price Target to $32

Citigroup analyst Patrick Cunningham maintains Huntsman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>) with a Neutral and lowers the price target from $12 to $11.

Citigroup Maintains Neutral on Huntsman, Lowers Price Target to $11

Citigroup analyst Jon Tower maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and raises the price target from $65 to $68.

Citigroup Maintains Buy on Chipotle Mexican Grill, Raises Price Target to $68

Drone stocks are taking off after hours Thursday after Defense Secretary Pete Hegseth issued new orders to fast-track <a href="https://www.benzinga.com/markets/commodities/25/06/45940533/us-military-drone-market-faces-overcrowding-amid-high-demand">drone manufacturing and deployment</a>.
What Happened: In a <a href="https://x.com/SecDef/status/1943401411431026977">video</a> posted on X after the market close on Thursday, Hegseth announced he was signing memos to rescind restrictive policies regarding drone production and deployment.
The memos, which are being shared by various accounts across social platforms, state that Hegseth plans to delegate authorities to procure and operate drones, deemed &#8220;vital&#8221; technology. 
&#8220;Lethality will not be hindered by self-imposed restrictions, especially when it comes to harnessing technologies we invented but were slow to pursue. Drone technology is advancing so rapidly, our major risk is risk-avoidance. The Department&#8217;s bureaucratic gloves are coming off,&#8221; Hegseth wrote in one of the memos. 
Several drone-related stocks were moving higher in Thursday&#8217;s after-hours session. Red Cat Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares were up 13.6% at $7.70, AeroVironment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) shares were up 3.34% at $245.50, Unusual Machines, Inc (AMIX:UMAC) shares were up 11.6% at $9.72 and AgEagle Aerial Systems Inc (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares were up 11% at $1.36. Ondas Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) shares were up 8.96% at $2.18 and Kratos Defense &amp; Security Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) shares were up 3.48% at $47.88. 
The news comes after President Donald Trump signed <a href="https://www.whitehouse.gov/articles/2025/06/president-trump-signs-executive-orders-on-drones-flying-cars-and-supersonics/">executive orders</a> in June aimed at strengthening domestic drone production and securing American airspace. The orders said the U.S. was enabling routine beyond line-of-sight operations to empower the domestic drone economy and addressing growing threats of foreign misuse of drones inside U.S. airspace.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46344520/defense-stocks-outperform-tech-trump-budget-boost">Forget Tech—Trump Just Made Defense The Hottest Trade On Wall Street</a></li>
</ul>
Photo: Shutterstock.

Government

Movers

AVAV

KTOS

ONDS

RCAT

UAVS

UMAC

Drone Stocks Fly As Defense Secretary Fast-Tracks Drone Production, Deployment

Citigroup analyst Christopher Allen maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Buy and raises the price target from $56 to $60.

Citigroup Maintains Buy on TPG, Raises Price Target to $60

Citigroup analyst Christopher Allen maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and raises the price target from $132 to $160.

Citigroup Maintains Buy on KKR, Raises Price Target to $160

Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) has outperformed the market over the past 15 years by 7.21% on an annualized basis producing an average annual return of 19.73%. Currently, Fiserv has a market capitalization of $94.12 billion. 
Buying $100 In FI: If an investor had bought $100 of FI stock 15 years ago, it would be worth $1,438.75 today based on a price of $169.75 for FI at the time of writing.
<h3>Fiserv's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752182124_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Fiserv 15 Years Ago Would Be Worth Today

Citigroup analyst Christopher Allen maintains Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Buy and raises the price target from $160 to $170.

Citigroup Maintains Buy on Apollo Asset Management, Raises Price Target to $170

Citigroup analyst James Hardiman maintains Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Buy and lowers the price target from $42 to $37.

Citigroup Maintains Buy on Six Flags Entertainment, Lowers Price Target to $37

Termination Rights
 &nbsp;
The Sandstorm Agreement contains certain termination rights for both Royal Gold and Sandstorm, including, among others: (i) mutual consent by Royal Gold and Sandstorm; (ii) by either party if the Sandstorm Arrangement shall not have been consummated on or prior to January 6, 2026 (which date may be extended until April 6, 2026 by either party if requisite regulatory approvals shall not have been obtained or denied by a non-appealable decision); (iii) by either party if after the date of the Sandstorm Agreement, there is enacted, made or enforced any applicable law, or any applicable law is amended, that makes consummation of the Sandstorm Arrangement illegal or otherwise prohibits or enjoins Royal Gold or Sandstorm from consummating the Sandstorm Arrangement and such applicable law, prohibition or enjoinment shall have become final and non-appealable; (iv) by either party if either the Sandstorm Requisite Shareholder Approval or Royal Gold Stockholder Approval shall not have been obtained; (v) by a party if the other party breaches any of its representations, warranties or covenants in the Sandstorm Agreement in a manner that would cause the corresponding condition to not be satisfied, subject to certain conditions; (vi) by a party if the other party's board of directors changes its recommendation with respect to the Sandstorm Arrangement or the other party breaches applicable non-solicitation restrictions in any material respect; (vii) by Royal Gold if the Horizon Agreement is terminated in accordance with its terms, subject to certain conditions, or Sandstorm shall have failed to comply with its obligations under a support and voting agreement entered into with Royal Gold; and (viii) by a party in order for such party to enter into a definitive agreement with respect to a superior competing business combination transaction prior to receiving approval from such party's shareholders (provided that such party has not materially breached the applicable non-solicitation restrictions).
 &nbsp;
If the Sandstorm Agreement is terminated in certain specified circumstances, Royal Gold or Sandstorm would be required to pay the other party a termination fee of $200 million or $130 million, respectively, or reimburse the other party for up to $5 million of expenses of the other party's representatives.

Contracts

RGLD

SAND

Royal Gold Says If Sandstorm Agreement Is Terminated Under Certain Circumstances, Royal Gold Or Sandstorm To Pay Other Party Termination Fee Of $200M Or $130M, Respectively

<a href="https://www.bloomberg.com/news/articles/2025-07-10/robinhood-s-crypto-trading-promotions-probed-by-florida-ag">https://www.bloomberg.com/news/articles/2025-07-10/robinhood-s-crypto-trading-promotions-probed-by-florida-ag</a>

General

HOOD

'Robinhood's Crypto Trading Promotions Probed by Florida AG'- Bloomberg

Citigroup analyst Carly Kenselaar maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Neutral and raises the price target from $155 to $176.

KRYS

Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $176

Second Quarter Preliminary Results
During the three months ended June 30, 2025, the Company sold approximately 15,100 attributable gold equivalent ounces1 and realized record preliminary revenue2 of $51.4 million (17,414 attributable gold equivalent ounces and $41.4 million in revenue for the comparable period in 2024).
Preliminary cost of sales, excluding depletion2 for the three months ended June 30, 2025, was $5.3 million resulting in record cash operating margins1 of approximately $2,980 per attributable gold equivalent ounce1 ($4.7 million and $2,043 per attributable gold equivalent ounce for the comparable period in 2024, respectively).
As at June 30, 2025, the outstanding balance on the Company's revolving credit facility was approximately $315 million with an undrawn and available balance of $310 million2.

Guidance

Sandstorm Gold Royalties Reports Preliminary Q2 2025 Revenue Of $51.4M And Cash Operating Margins Of $2,980/Oz On 15,100 Gold Equivalent Ounces Sold

Health Care

Press Releases

Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Small Cap

Opinion

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Financing

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform  Landscape of Cancer Treatment

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

CGON

CLDI

CRSP

CTMX

IBRX

IMRX

KZIA

NUVB

ONCY

REGN

RHHBF

RHHBY

TSX:ONC

VRTX

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

Elevation Oncology

FibroGen

Generation Bio

Geovax Labs

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

NuCana

Nanoviricides

OSR Holdings

Plus Therapeutics

Q32 Bio

Rallybio

SAB Biotherapeutics

Tenax Therapeutics

Ladenburg Thalmann

Baird

HC Wainwright & Co.

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

CADL

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Comments

Calidi Biotherapeutics

Actualités

Dernières nouvelles pour Calidi Biotherapeutics (AMEX:CLDI) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL